![Brian Burkavage](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Brian Burkavage
Finanzdirektor/CFO bei
DAMORA THERAPEUTICS, INC.
Vermögen: - $ am 31.08.2026
Profil
Brian Burkavage is Chief Financial & Accounting Officer at Damora Therapeutics, Inc. starting in 2026.
Former positions include Chief Accounting Officer at IO Biotech, Inc. from 2022 to 2025, Controller at Passage Bio, Inc. from 2020 to 2021, and Director-Financial Planning & Analysis at Aclaris Therapeutics, Inc. from 2017 to 2020.
Education includes undergraduate and graduate degrees from the University of Notre Dame.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
IO BIOTECH, INC. 0.02% | 02.04.2025 | 11’500 ( 0.02% ) | - $ | 31.08.2026 |
Aktive Positionen von Brian Burkavage
| Unternehmen | Position | Beginn |
|---|---|---|
| DAMORA THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.05.2026 |
Ehemalige bekannte Positionen von Brian Burkavage
| Unternehmen | Position | Ende |
|---|---|---|
| IO BIOTECH, INC. | Comptroller/Controller/Auditor | 12.12.2025 |
| PASSAGE BIO, INC. | Comptroller/Controller/Auditor | 01.01.2021 |
| ACLARIS THERAPEUTICS, INC. | Corporate Officer/Principal | 01.01.2020 |
Ausbildung von Brian Burkavage
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
56
Beziehungen ersten Grades
5
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
University of Notre Dame
 University of Notre Dame Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aclaris Therapeutics, Inc.
 Aclaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel drug candidates for immuno-inflammatory diseases | Health Technology |
Passage Bio, Inc.
 Passage Bio, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of monogenic central nervous system disorders | Health Technology |
Galecto, Inc.
 Galecto, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for treatment of severe diseases | Health Technology |
IO Biotech, Inc.
 IO Biotech, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops novel, immune-modulating cancer therapies | Health Technology |
